Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

454.00 -4.05 (-0.88%)

Official Closing Price Updated: 4:15 PM EDT, Mar 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

72 73 Next >

ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades' ↗

October 03, 2025

Jason Snipe likes ServiceNow (NOW), down 14% YTD. Morgan Stanley upgraded to Overweight. Shannon Saccocia chose iShares Core S&P Small-Cap ETF. Jim Lebenthal recommends Vertex Pharmaceuticals (VRTX).

Via Benzinga

Topics ETFs Stocks

Apple To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Thursday ↗

October 02, 2025

Via Benzinga

Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design

October 02, 2025

London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented...

Via TokenRing AI

Topics Artificial Intelligence

Healthcare Sector Defies Headwinds, Rallies on Wall Street Amidst Shutdown and Jobs Data

October 01, 2025

New York, NY – October 1, 2025 – In a surprising turn of events on Wall Street today, the healthcare sector emerged as the undisputed leader, shrugging off the dual anxieties of a U.S. government...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

10 Health Care Stocks Whale Activity In Today's Session ↗

October 01, 2025

Via Benzinga

What Does the Market Think About Vertex Pharmaceuticals Inc? ↗

September 30, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2025

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

2 S&P 500 Stocks to Research Further and 1 We Avoid

September 29, 2025

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...

Via StockStory

Topics Stocks

5 Top Stocks to Buy in October ↗

September 28, 2025

These five stocks are underperforming the S&P 500 in 2025, but have what it takes to reward investors over the long term.

Via The Motley Fool

Topics Stocks

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

President Donald Trump threatened 100% tariffs on some drug imports.

Via Investor's Business Daily

Topics ETFs Government World Trade

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗

September 25, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Assessing Vertex Pharmaceuticals: Insights From 15 Financial Analysts ↗

September 25, 2025

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Via Benzinga

Vertex Announces Key Advancements Across Kidney Portfolio

September 25, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

This Chewy Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

September 25, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...

Via Benzinga

My 3 Favorite Stocks to Buy Right Now ↗

September 25, 2025

Uncertainty is in the air. But these stocks inspire confidence.

Via The Motley Fool

Topics Artificial Intelligence Economy

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Top GARP Stock ↗

September 24, 2025

Vertex Pharmaceuticals (VRTX) is a top GARP stock, offering strong revenue growth, high profitability, and a debt-free balance sheet at a reasonable valuation.

Via Chartmill

Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain

September 23, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Unpacking Q2 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks

September 22, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex...

Via StockStory

Topics Artificial Intelligence

Healthcare Stocks Are at an Historic Low and a Turnaround Is on the Horizon ↗

September 20, 2025

There is a "for sale" sign on the sector, and these two stocks look particularly attractive at their current levels.

Via The Motley Fool

Topics Government Intellectual Property World Trade

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

Via Benzinga

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

September 18, 2025

From Vertex Pharmaceuticals

Via Business Wire

2 Growth Stocks to Buy and Hold Forever ↗

September 17, 2025

Look beyond the recent headwinds these two have faced.

Via The Motley Fool

Topics World Trade

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Screens as a Top Undervalued Stock with Strong Fundamentals ↗

September 17, 2025

Vertex Pharmaceuticals (VRTX) is a strong value stock with high profitability, zero debt, and solid growth, trading at an attractive valuation within the biotech sector.

Via Chartmill

Why This Biotech Company Could Be a Growth Stock Powerhouse ↗

September 17, 2025

The stock has soared in the triple-digits over the past decade.

Via The Motley Fool

1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals ↗

September 15, 2025

Here's why you can't find a Wall Street analyst who will tell you to sell this stock.

Via The Motley Fool

Topics Intellectual Property

3 Absurdly Cheap Stocks to Buy for the Long Haul ↗

September 12, 2025

They trade at some incredibly low earnings multiples.

Via The Motley Fool

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years ↗

September 11, 2025

Via Benzinga

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

September 11, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Fundamentals and Technical Breakout Potential ↗

September 11, 2025

Vertex Pharmaceuticals (VRTX) is a top growth stock with strong fundamentals, high profitability, and a technical setup hinting at a potential breakout for investors.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

72 73 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.